| HORIZON | TRADES | WIN RATE | INSIDER RETURN | SPY RETURN | MEAN EXCESS | MEDIAN EXCESS | T-STAT |
|---|---|---|---|---|---|---|---|
| 7d | 2 | +0.00% | +26.21% | +0.89% | +25.32% | +25.32% | — |
| 14d | 2 | +0.00% | +37.57% | -0.98% | +38.56% | +38.56% | — |
| 30d | 2 | +50.00% | -0.41% | +0.91% | -1.32% | -1.32% | — |
| 60d | 2 | +50.00% | -5.84% | -0.23% | -5.61% | -5.61% | — |
| 90d | 2 | +50.00% | -4.88% | -0.70% | -4.18% | -4.18% | — |
| 180d | 2 | +50.00% | +24.75% | +1.42% | +23.33% | +23.33% | — |
| 1y | 2(2 pending) | — | — | — | — | — | — |
| 2y | 2(2 pending) | — | — | — | — | — | — |
| COMPANY | TYPE | SHARES | PRICE | VALUE | HELD AFTER | TRADE DATE | FILED | DETAILS |
|---|---|---|---|---|---|---|---|---|
| NTLA INTELLIA THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 39,200 | — | — | 137,733 | Mar 1, 2026 | Mar 3, 2026 ↗ | View → |
| NTLA INTELLIA THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 56,000 | — | — | 56,000 | Mar 1, 2026 | Mar 3, 2026 ↗ | View → |
| NTLA INTELLIA THERAPEUTICS, INC. | SALE EVP, Chief Scientific Officer | 8,508 | $9.21 | $78.4K | 98,533 | Jan 5, 2026 | Jan 7, 2026 ↗ | View → |
| NTLA INTELLIA THERAPEUTICS, INC. | SALE EVP, Chief Scientific Officer | 31 | $17.38 | $539 | 105,184 | Oct 1, 2025 | Oct 3, 2025 ↗ | View → |
| NTLA INTELLIA THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 37,600 | — | — | 105,215 | Mar 1, 2025 | Mar 4, 2025 ↗ | View → |
| NTLA INTELLIA THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 53,714 | — | — | 53,714 | Mar 1, 2025 | Mar 4, 2025 ↗ | View → |